Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Francois Brisebois maintains a Buy rating on MapLight Therapeutics with a $45 price target, citing the upcoming Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia and strong commercial potential. He highlights the company's solid two-year cash runway and positive risk-reward outlook. This follows a June 25 initiation by Raymond James, which also issued a Buy rating with a $46 target.
Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on MapLight Therapeutics, Inc., retaining the price target of $45.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Francois Brisebois has given his Buy rating due to a combination of factors, notably the upcoming Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia and the drug’s perceived commercial opportunity. He views the planned KOL event with leading schizophrenia experts as an important validation step, underscoring credible interest in 007’s clinical profile and market positioning.
He also highlights MapLight Therapeutics’ solid funding runway, with roughly two years of cash based on current burn, which supports execution through key data milestones without immediate financing pressure. Against this backdrop, he maintains a favorable risk‑reward outlook and keeps his $45 price target unchanged, reflecting confidence that positive Phase 2 data could meaningfully unlock value despite development and market risks.
According to TipRanks, Brisebois is a 4-star analyst with an average return of 5.9% and a 41.95% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Savara, and Definium Therapeutics.
In another report released on June 25, Raymond James also initiated coverage with a Buy rating on the stock with a $46.00 price target.